Influenza viruses are major human respiratory pathogens that
cause high morbidity and mortality worldwide. Currently,
prophylactic vaccines and therapeutic antiviral agents are used
to prevent and control influenza virus infection. Oseltamivir
free base (OSV-FB), a modified generic antiviral drug of
Tamiflu (oseltamivir phosphate, OSV-P), was launched in
the Republic of Korea last year. Here, we examine the bioequivalence
of these two compounds by assessing their antiviral
efficacy in infected cells and in a mouse model. It was
observed that both antivirals showed comparable efficacy
against 11 different influenza A and B viruses in vitro. Moreover,
in mice infected with influenza A virus (mouse-adapted
A/Puerto Rico/8/34), they showed a dose-dependent therapeutic
activity and alleviated infection-mediated reductions
in body weight, leading to significantly better survival. There
was histopathological disappearance of virus-induced inflammatory
cell infiltration of the lung after oral treatment with
either antiviral agent (at 10 mg/kg). Pharmacokinetic analysis
also exhibited similar plasma concentrations of the active
drug, oseltamivir carboxylate, metabolised from both OSVB
and OSV-P. This is the first report showing bioequivalence
of OSV-FB to its phosphate salt form in the mouse system.
The free base drug has some beneficial points including simple
drug formulation process and reduced risk of undesirable
cation-phosphate precipitation within solution. The long term
stability of OSV-FB requires further monitoring when it is
provided as a national stock in readiness for an influenza
pandemic.
Citations
Citations to this article as recorded by
Interaction mechanism of oseltamivir phosphate with bovine serum albumin: multispectroscopic and molecular docking study Jing Yu, Jian-Ming Liu, Hui-Yi Chen, Wei-Ming Xiong BMC Chemistry.2024;[Epub] CrossRef
A Lysosome-Targeting hNEU1 Inhibitor Treats Myocardial Infarction: A Potential Therapeutic Breakthrough Wen Zhou, Wanxiang Yang, Ping Jiang, Shaohua Gou Journal of Medicinal Chemistry.2024; 67(18): 16899. CrossRef
The possible techniques that used to improve the bioavailablity, pharmacological activity, solubility and permeability of anti-viral drugs: Insight for COVID-19 antiviral drugs Ghassan Mudher Hashim , Ghaidaa S. Hameed , Dalya Basil Hanna Al Mustansiriyah Journal of Pharmaceutical Sciences.2023; 23(3): 231. CrossRef
Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics Ran Chen, Tingting Wang, Jie Song, Daojun Pu, Dan He, Jianjun Li, Jie Yang, Kailing Li, Cailing Zhong, Jingqing Zhang International Journal of Nanomedicine.2021; Volume 16: 4959. CrossRef
Multistage Extraction of Star Anise and Black Pepper Derivatives for Antibacterial, Antioxidant, and Anticancer Activity Helin Li, Xiaoyu Wu, Xin Li, Xiaobing Cao, Yanjun Li, Huaru Cao, Yongzhi Men Frontiers in Chemistry.2021;[Epub] CrossRef
Development of Sustained Release Oseltamivir Phosphate Dry Powder Inhaler: In-Vitro Characterization and In-Vivo Toxicological Studies Harshal Sahastrabudhe, Prathmesh Kenjale, Varsha Pokharkar Current Drug Delivery.2020; 17(8): 703. CrossRef
In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus Yejin Jang, Jin Soo Shin, Joo-Youn Lee, Heegwon Shin, Sang Jick Kim, Meehyein Kim Viruses.2020; 12(5): 581. CrossRef
A new naphthoquinone analogue and antiviral constituents from the root of Rhinacanthus nasutus Tran Minh Ngoc, Nguyen Thi Thanh Phuong, Nguyen Minh Khoi, SeonJu Park, Hee Jae Kwak, Nguyen Xuan Nhiem, Bui Thi Thu Trang, Bui Huu Tai, Jae-Hyoung Song, Hyun-Jeong Ko, Seung Hyun Kim Natural Product Research.2019; 33(3): 360. CrossRef
Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function Yejin Jang, Jin Soo Shin, Yi-Seul Yoon, Yun Young Go, Hye Won Lee, Oh Seung Kwon, Sehee Park, Man-Seong Park, Meehyein Kim, Jae U. Jung Journal of Virology.2018;[Epub] CrossRef
The Cranberry Extract Oximacro® Exerts in vitro Virucidal Activity Against Influenza Virus by Interfering With Hemagglutinin Anna Luganini, Maria E. Terlizzi, Gianluca Catucci, Gianfranco Gilardi, Massimo E. Maffei, Giorgio Gribaudo Frontiers in Microbiology.2018;[Epub] CrossRef